Double maintains 2 strategies that include SNDX - Syndax Pharmaceuticals, Inc.
Finnhub
Presenter SpeechJason Zemansky Here on this our third day of Bank of America's 2025 Healthcare Conference in Las Vegas. My name is Jason Zemansky. I'm one of the mid-cap analysts here at the bank....
Yahoo
– Revumenib abstracts highlight compelling results in acute leukemia across the frontline and R/R setting and multiple genetic populations, including mNPM1, KMT2Ar, and NUP98r – – Axatilimab abstracts highlight the robust responses observed in different organs and subgroups of patients with chronic GVHD in the AGAVE-201 trial – NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, toda
Yahoo
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R&D strategy and global commercialization of novel oncology therapeutics - NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the appointment of Dr. Nicholas Botwood BSc (Hons), MBBS, MFPM, FRCP, to the role of Head of Research and Development (R&D) an
Yahoo
The consensus price target hints at a 220% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Bank of America Merrill Lynch Vegas Health Care Conference with a fireside chat on Thursday, May 15, 2025, at 9:20 a.m. PT/ 12:20 p.m. ET.TD Co
Yahoo
– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial – – Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate – – sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 – NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 por
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -34.82% | $109.64M | 0.85% |
TAIL | -34.81% | $140.49M | 0.59% |
BTAL | -31.17% | $361.41M | 1.43% |
FTSD | -19.53% | $212.46M | 0.25% |
IVOL | -18.07% | $353.94M | 1.02% |
CLIP | -15.56% | $1.50B | 0.07% |
SHYM | -12.78% | $322.93M | 0.35% |
CTA | -11.54% | $1.05B | 0.76% |
FXY | -11.07% | $838.61M | 0.4% |
TPMN | -10.04% | $31.54M | 0.65% |
FXE | -9.30% | $525.40M | 0.4% |
SPTS | -8.35% | $5.76B | 0.03% |
UTWO | -8.16% | $387.71M | 0.15% |
BSMW | -8.13% | $102.62M | 0.18% |
UNG | -7.51% | $371.83M | 1.06% |
IBTH | -7.47% | $1.53B | 0.07% |
SCHO | -7.21% | $10.87B | 0.03% |
TBLL | -7.13% | $2.46B | 0.08% |
IBTF | -6.81% | $2.12B | 0.07% |
UDN | -6.65% | $137.74M | 0.78% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FMB | 0.03% | $1.91B | 0.65% |
IBMS | 0.05% | $69.47M | 0.18% |
GSST | 0.07% | $857.21M | 0.16% |
TFLO | -0.09% | $7.06B | 0.15% |
IGOV | 0.19% | $994.85M | 0.35% |
IBND | 0.20% | $291.26M | 0.5% |
JMST | -0.21% | $3.65B | 0.18% |
MMIT | 0.22% | $829.60M | 0.3% |
XBIL | 0.24% | $782.40M | 0.15% |
IEF | 0.39% | $34.17B | 0.15% |
WEAT | -0.45% | $115.83M | 0.28% |
BSSX | 0.46% | $75.11M | 0.18% |
CMF | 0.47% | $3.57B | 0.08% |
TYA | -0.50% | $149.38M | 0.15% |
CORN | 0.50% | $49.57M | 0.2% |
BSMR | -0.51% | $245.57M | 0.18% |
GLDM | 0.57% | $14.42B | 0.1% |
ITM | -0.66% | $1.97B | 0.18% |
TBIL | -0.66% | $5.76B | 0.15% |
BSV | -0.67% | $38.35B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 61.24% | $4.85B | 0.35% |
GNOM | 57.18% | $40.65M | 0.5% |
IBB | 56.89% | $5.22B | 0.45% |
BTC | 55.81% | $4.48B | 0.15% |
PBE | 51.39% | $214.12M | 0.58% |
BBH | 49.24% | $327.42M | 0.35% |
PINK | 49.06% | $131.52M | 0.5% |
XPH | 48.87% | $136.58M | 0.35% |
IWC | 48.53% | $766.88M | 0.6% |
FBT | 48.13% | $994.71M | 0.56% |
VTWO | 47.37% | $12.07B | 0.07% |
VHT | 47.29% | $14.92B | 0.09% |
PTH | 47.28% | $96.56M | 0.6% |
ARKG | 47.20% | $944.78M | 0.75% |
IWM | 47.16% | $63.95B | 0.19% |
IWO | 46.98% | $11.36B | 0.24% |
FHLC | 46.93% | $2.42B | 0.084% |
KJUL | 45.82% | $113.35M | 0.79% |
IWN | 45.75% | $11.10B | 0.24% |
SCHA | 45.72% | $16.91B | 0.04% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BTCT | -29.52% | $25.35M | +93.08% | 0.00% |
MNOV | -18.38% | $68.17M | -2.80% | 0.00% |
AIFU | -13.18% | $9.85M | -95.03% | 0.00% |
AQB | -13.14% | $2.96M | -61.58% | 0.00% |
K | -8.90% | $28.49B | +32.17% | 2.77% |
FMTO | -8.12% | $45.74M | -99.96% | 0.00% |
LITB | -7.56% | $21.28M | -72.45% | 0.00% |
AMTX | -7.07% | $90.25M | -58.31% | 0.00% |
BAH | -4.39% | $16.17B | -16.31% | 1.64% |
CBOE | -3.94% | $22.95B | +20.67% | 1.12% |
FARO | -3.36% | $812.11M | +115.84% | 0.00% |
FUBO | -2.89% | $1.01B | +121.80% | 0.00% |
EGO | -2.53% | $3.68B | +17.14% | 0.00% |
HSY | -2.46% | $33.16B | -21.37% | 3.44% |
CODI | -2.28% | $580.07M | -65.16% | 12.97% |
BJ | -2.16% | $14.71B | +39.60% | 0.00% |
MUSA | -2.06% | $8.91B | +2.63% | 0.53% |
VHC | -2.00% | $34.69M | +74.89% | 0.00% |
SAIC | -1.97% | $5.75B | -10.80% | 1.22% |
AWK | -1.95% | $27.37B | +4.54% | 2.22% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
KYMR | 52.03% | $1.95B | -15.67% | 0.00% |
KRYS | 50.82% | $3.77B | -20.42% | 0.00% |
IDYA | 50.56% | $1.52B | -58.32% | 0.00% |
RNA | 48.06% | $3.49B | +0.87% | 0.00% |
ATXS | 48.00% | $225.17M | -57.69% | 0.00% |
RARE | 47.94% | $3.29B | -18.24% | 0.00% |
ACLX | 47.92% | $3.22B | +10.72% | 0.00% |
RVMD | 45.96% | $7.35B | +1.15% | 0.00% |
PGY | 45.92% | $1.06B | +19.08% | 0.00% |
XNCR | 45.78% | $583.60M | -63.49% | 0.00% |
CRNX | 45.78% | $2.92B | -39.88% | 0.00% |
XENE | 45.64% | $2.27B | -26.70% | 0.00% |
BEAM | 45.45% | $1.73B | -27.49% | 0.00% |
CRH | 45.38% | $66.31B | +18.04% | 0.00% |
DNLI | 45.20% | $2.06B | -30.04% | 0.00% |
BHVN | 45.09% | $1.62B | -58.86% | 0.00% |
RCKT | 44.35% | $724.54M | -71.26% | 0.00% |
REPL | 44.32% | $556.82M | +7.59% | 0.00% |
DAWN | 43.53% | $624.39M | -61.57% | 0.00% |
RGNX | 43.50% | $433.39M | -46.03% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HUSA | -0.33% | $9.73M | -55.71% | 0.00% |
ICFI | 0.33% | $1.63B | -39.65% | 0.64% |
PSN | 0.40% | $7.29B | -10.84% | 0.00% |
WBA | 0.41% | $9.67B | -39.04% | 6.69% |
DVA | 0.50% | $10.84B | +5.22% | 0.00% |
PRPO | 0.55% | $10.84M | +15.14% | 0.00% |
HCA | 0.58% | $92.74B | +19.46% | 0.70% |
CNK | 0.60% | $3.67B | +78.94% | 0.25% |
UONEK | 0.61% | $28.82M | -65.93% | 0.00% |
CCEC | 0.61% | $1.02B | +3.91% | 2.71% |
ACHC | 0.65% | $2.36B | -61.52% | 0.00% |
NEUE | 0.67% | $62.05M | +13.56% | 0.00% |
OCX | 0.71% | $79.79M | -9.12% | 0.00% |
PHYS.U | 0.79% | - | - | 0.00% |
FYBR | 0.80% | $9.16B | +36.87% | 0.00% |
CARV | -0.81% | $7.41M | -22.87% | 0.00% |
CREG | 0.83% | $16.80M | -32.73% | 0.00% |
EVGO | -0.93% | $532.65M | +68.22% | 0.00% |
VSA | 0.98% | $7.04M | -49.24% | 0.00% |
BULL | 1.06% | $5.67B | +11.22% | 0.00% |
Current Value
$8.971 Year Return
Current Value
$8.971 Year Return